Sophie C Lee1, Steven Tran2, Aana Amin1, Lawrence S Morse1, Ala Moshiri1, Susanna S Park1, Glenn Yiu3. 1. Department of Ophthalmology and Vision Science, University of California, Davis, Sacramento, California. 2. Department of Ophthalmology and Vision Science, University of California, Davis, Sacramento, California; Rosalind Franklin University of Medicine and Science, North Chicago, Illinois. 3. Department of Ophthalmology and Vision Science, University of California, Davis, Sacramento, California. Electronic address: gyiu@ucdavis.edu.
Abstract
PURPOSE: Although the choroid contributes to the pathogenesis of age-related macular degeneration (AMD), the role of retinal perfusion is unclear. We sought to compare retinal vascular measurements between eyes with nonexudative and exudative AMD using optical coherence tomography angiography (OCT-A). DESIGN: Retrospective, cross-sectional study. METHODS: OCT-A images were analyzed from 310 eyes of 182 patients (mean age ± standard deviation [SD], 78.8 ± 8.8 years) with nonexudative (54.2%) and exudative (45.8%) AMD to measure retinal vessel density (VD) from the superficial capillary plexus in the foveal, parafoveal, and full macular regions and foveal avascular zone (FAZ) area, perimeter, and circularity. Multivariate regressions were used to compare nonexudative and exudative AMD eyes and the impact of anti-vascular endothelial growth factor (anti-VEGF) treatments or geographic atrophy (GA). RESULTS: In eyes with AMD, VD decreases with age in the foveal (β = -0.211, P < .001), parafoveal (β = -0.305, P < .001), and full macular regions (β = -0.295, P < .001). Eyes with exudative AMD demonstrated lower VD, especially in the parafoveal (29.8% ± 6.3% vs 33.0% ± 5.7%, P < .001) and full regions (27.9% ± 6.2% vs 31.2% ± 5.5%, P < .001) compared with nonexudative AMD. There were no differences in FAZ area, perimeter, or circularity between the 2 groups (P = .503-.907). In eyes with exudative AMD, previous anti-VEGF treatments did not impact retinal vascular measurements (P = .324-.986). Nonexudative AMD severity and presence of central GA also impacted retinal VD and FAZ morphology. CONCLUSIONS: Retinal VD is decreased in eyes with exudative AMD compared with nonexudative AMD but is unaffected by anti-VEGF treatments, suggesting a retinal vascular contribution to the pathogenesis of AMD.
PURPOSE: Although the choroid contributes to the pathogenesis of age-related macular degeneration (AMD), the role of retinal perfusion is unclear. We sought to compare retinal vascular measurements between eyes with nonexudative and exudative AMD using optical coherence tomography angiography (OCT-A). DESIGN: Retrospective, cross-sectional study. METHODS:OCT-A images were analyzed from 310 eyes of 182 patients (mean age ± standard deviation [SD], 78.8 ± 8.8 years) with nonexudative (54.2%) and exudative (45.8%) AMD to measure retinal vessel density (VD) from the superficial capillary plexus in the foveal, parafoveal, and full macular regions and foveal avascular zone (FAZ) area, perimeter, and circularity. Multivariate regressions were used to compare nonexudative and exudative AMD eyes and the impact of anti-vascular endothelial growth factor (anti-VEGF) treatments or geographic atrophy (GA). RESULTS: In eyes with AMD, VD decreases with age in the foveal (β = -0.211, P < .001), parafoveal (β = -0.305, P < .001), and full macular regions (β = -0.295, P < .001). Eyes with exudative AMD demonstrated lower VD, especially in the parafoveal (29.8% ± 6.3% vs 33.0% ± 5.7%, P < .001) and full regions (27.9% ± 6.2% vs 31.2% ± 5.5%, P < .001) compared with nonexudative AMD. There were no differences in FAZ area, perimeter, or circularity between the 2 groups (P = .503-.907). In eyes with exudative AMD, previous anti-VEGF treatments did not impact retinal vascular measurements (P = .324-.986). Nonexudative AMD severity and presence of central GA also impacted retinal VD and FAZ morphology. CONCLUSIONS:Retinal VD is decreased in eyes with exudative AMD compared with nonexudative AMD but is unaffected by anti-VEGF treatments, suggesting a retinal vascular contribution to the pathogenesis of AMD.
Authors: Enrico Borrelli; Eric H Souied; K Bailey Freund; Giuseppe Querques; Alexandra Miere; Orly Gal-Or; Riccardo Sacconi; SriniVas R Sadda; David Sarraf Journal: Retina Date: 2018-10 Impact factor: 4.256
Authors: Eric M Moult; Agha Yasin Alibhai; Carl Rebhun; ByungKun Lee; Stefan Ploner; Julia Schottenhamml; Lennart Husvogt; Caroline R Baumal; Andre J Witkin; Andreas Maier; Jay S Duker; Phillip J Rosenfeld; Nadia K Waheed; James G Fujimoto Journal: Retina Date: 2020-03 Impact factor: 3.975
Authors: Tu M Tran; Soohyun Kim; Kira H Lin; Sook Hyun Chung; Sangwan Park; Yevgeniy Sazhnyev; Yinwen Wang; David Cunefare; Sina Farsiu; Sara M Thomasy; Ala Moshiri; Glenn Yiu Journal: Invest Ophthalmol Vis Sci Date: 2020-07-01 Impact factor: 4.799